Repligen Corporation (RGEN) - 10-K Summary
Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2003
Business Overview: Repligen is a biotechnology company developing therapeutic products for pediatric developmental disorders (autism, schizophrenia), autoimmune disorders, and neurologic/metabolic diseases. Its strategy involves funding these development programs through profits from specialty pharmaceutical products: recombinant Protein A (for antibody purification) and SecreFlo(TM) (a diagnostic secretin product).
Key Financial Metrics (Fiscal Year 2003)
| Metric | 2003 (in thousands) | 2002 (in thousands) |
|---|---|---|
| Total Revenue | $7,772 | $4,302 |
| Cost of Revenue | $3,480 | $1,993 |
| Gross Profit | $4,292 | $2,309 |
| Gross Margin | 55% | 54% |
| Operating Expenses | $9,386 | $7,887 |
| Net Loss | $(4,537) | $(4,461) |
| Cash & Marketable Securities | $18,909 | $25,250 |
| Working Capital | $15,602 | $20,577 |
Debt & Liquidity: The company reported no long-term debt. Liquidity is supported by cash and marketable securities of approximately $18.9 million. The company has net operating loss carryforwards of approximately $122.4 million and R&D tax credit carryforwards of $7.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 81% to $7.77 million, driven by the commercial launch of SecreFlo(TM) in October 2002 and increased demand for Protein A products.
- Operating Expenses: Increased 19% to $9.39 million. Selling, General, and Administrative (SG&A) expenses rose 65% due to increased staffing, investor relations, and litigation costs, partially offset by reimbursements from a licensing partner.
- Investment Income: Decreased 50% to $557,000 due to lower interest rates and reduced average funds available for investment.
- Stock Price: The common stock traded between $2.05 and $5.00 during fiscal 2003.
Guidance, Outlook, and Risks
Outlook: Management anticipates significantly higher costs in fiscal 2004 due to expanded clinical trials for proprietary drug candidates and the commercialization of SecreFlo(TM). The company believes current resources are sufficient for the next 24 months but may require additional financing.
Recent Capital Raise: In May 2003 (subsequent to period end), the company completed a private placement of 2.5 million shares, raising approximately $11.8 million in net proceeds.
Key Risks & Contingencies:
- Clinical Trial Success: Future viability depends on the success of Phase 3 trials for Secretin (autism) and Phase 2 trials for Schizophrenia and Uridine.
- Legal Proceedings:
- Pro-Neuron Litigation: Settled in June 2003; Repligen to receive $750,000 but must discontinue mitochondrial disease trials for acylated pyrimidines.
- ChiRhoClin Arbitration: Partner claims ~$800,000 in damages regarding royalty calculations; Repligen disputes the claim.
- Bristol-Myers Squibb Litigation: Ongoing dispute regarding inventorship of CTLA4-Ig patents; outcome could restrict commercialization rights.
- Regulatory Approval: Delays or failures in FDA approvals for therapeutic candidates would materially harm the business.
Investor Verification Checklist
- SecreFlo(TM) Sales Trajectory: Verify if sales volumes for the new diagnostic product are meeting management's projections to offset R&D burn.
- Clinical Trial Enrollment: Confirm patient enrollment rates for the Phase 3 Secretin autism trials and Phase 2 Schizophrenia trials.
- Legal Settlement Impact: Assess the long-term impact of the Pro-Neuron settlement on the Uridine development pipeline.
- Customer Concentration: Note that 66% of foreign revenue in 2003 came from just two customers (Amersham and Applied Biosystems).
- Cash Runway: Monitor the burn rate relative to the $18.9 million cash balance and the $11.8 million raised in May 2003.